{"id":"casirivimab","rwe":[{"pmid":"41884818","year":"2026","title":"The role of large immune complexes in anti-drug antibody development: a case study of anti-SARS-CoV-2 antibody therapeutics and co-administered mRNA vaccine.","finding":"","journal":"Frontiers in immunology","studyType":"Clinical Study"},{"pmid":"41771484","year":"2026","title":"Effect of background asthma and allergic conditions on prophylaxis and treatment of COVID-19 infection.","finding":"","journal":"Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology","studyType":"Clinical Study"},{"pmid":"41612083","year":"2026","title":"Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations.","finding":"","journal":"PharmacoEconomics - open","studyType":"Clinical Study"},{"pmid":"41598229","year":"2026","title":"REGEN-COV as the First Line of Defense-A Single-Centre Experience.","finding":"","journal":"Life (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41278696","year":"2025","title":"A cocktail of SARS-CoV-2 spike stem helix domain and receptor binding domain human monoclonal antibodies prevent the emerge of viral escape mutants.","finding":"","journal":"bioRxiv : the preprint server for biology","studyType":"Clinical Study"}],"tags":[{"label":"Monoclonal Antibody","category":"modality"},{"label":"J06BD07","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Active","category":"status"},{"label":"COVID-19","category":"indication"},{"label":"Regeneron Pharmaceuticals, Inc.","category":"company"},{"label":"Approved 2020s","category":"decade"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":215.627,"date":"","count":47,"signal":"Wrong product administered","source":"DrugCentral FAERS","actionTaken":"Reported 47 times (LLR=216)"},{"llr":208.844,"date":"","count":97,"signal":"Infusion related reaction","source":"DrugCentral FAERS","actionTaken":"Reported 97 times (LLR=209)"},{"llr":151.47,"date":"","count":42,"signal":"COVID-19 pneumonia","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=151)"},{"llr":86.584,"date":"","count":38,"signal":"Hypoxia","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=87)"},{"llr":84.723,"date":"","count":85,"signal":"Dyspnoea","source":"DrugCentral FAERS","actionTaken":"Reported 85 times (LLR=85)"},{"llr":65.566,"date":"","count":35,"signal":"Oxygen saturation decreased","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=66)"},{"llr":62.678,"date":"","count":30,"signal":"Flushing","source":"DrugCentral FAERS","actionTaken":"Reported 30 times (LLR=63)"}],"commonSideEffects":[],"specialPopulations":{"Pregnancy":"There are insufficient data to evaluate drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. REGEN-COV (casirivimab and imdevimab) should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.","Geriatric use":"Of the 4,567 subjects with SARS-CoV-2 infection randomized in Trial COV-2067, 14% were 65 years or older, and 4% were 75 years of age or older.","Paediatric use":"REGEN-COV is not authorized for use in pediatric patients under 12 years of age or weighing less than 40 kg. The safety and effectiveness of casirivimab and imdevimab are being assessed in pediatric and adolescent patients in an ongoing clinical trial."}},"trials":[],"aliases":[],"company":"Regeneron Pharmaceuticals, Inc.","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CASIRIVIMAB","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:27:19.715590+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:27:26.386682+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:27:19.735421+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CASIRIVIMAB","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:27:27.148712+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Spike glycoprotein inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:27:27.701650+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4650248/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:27:27.605972+00:00"}},"allNames":"ronapreve","offLabel":[],"synonyms":["casirivimab","REGN10933","regen-cov","ronapreve"],"timeline":[{"date":"2020-11-21","type":"positive","source":"DrugCentral","milestone":"FDA approval (Regeneron Pharmaceuticals, Inc.)"},{"date":"2021-07-19","type":"positive","source":"DrugCentral","milestone":"PMDA approval (CHUGAI PHARMACEUTICAL Co., Ltd)"},{"date":"2021-11-12","type":"positive","source":"DrugCentral","milestone":"EMA approval (Roche Registration Gmbh)"}],"aiSummary":"Ronapreve (Casirivimab) is a monoclonal antibody developed by Regeneron Pharmaceuticals, Inc. It is used to treat COVID-19 and works by binding to the SARS-CoV-2 virus, preventing it from entering host cells. Ronapreve is a patented medication with FDA approval since 2020. Key safety considerations include potential allergic reactions and the risk of transmission of COVID-19 despite treatment. As a monoclonal antibody, Ronapreve is a large molecule, not a small molecule.","brandName":"Ronapreve","ecosystem":[{"indication":"COVID-19","otherDrugs":[{"name":"bamlanivimab","slug":"bamlanivimab","company":"Eli Lilly and Company"},{"name":"etesevimab","slug":"etesevimab","company":"Eli Lilly and Company"},{"name":"imdevimab","slug":"imdevimab","company":"Regeneron Pharmaceuticals, Inc."},{"name":"nirmatrelvir","slug":"nirmatrelvir","company":"Pfizer, Inc."}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Monoclonal Antibody","explanation":"","oneSentence":"","technicalDetail":"Ronapreve is a monoclonal antibody that binds to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, thereby preventing the virus from attaching to and entering host cells."},"commercial":{"launchDate":"2020","_launchSource":"DrugCentral (FDA 2020-11-21, Regeneron Pharmaceuticals, Inc.)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5455","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CASIRIVIMAB","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CASIRIVIMAB","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T09:11:26.831182","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:27:29.463539+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"palivizumab","drugSlug":"palivizumab","fdaApproval":"1998-06-19","relationship":"same-class"},{"drugName":"ansuvimab","drugSlug":"ansuvimab","fdaApproval":"2020-12-21","relationship":"same-class"},{"drugName":"imdevimab","drugSlug":"imdevimab","fdaApproval":"2020-11-21","relationship":"same-class"},{"drugName":"nirsevimab","drugSlug":"nirsevimab","fdaApproval":"2023-07-17","relationship":"same-class"}],"genericName":"casirivimab","indications":{"approved":[{"name":"COVID-19","source":"DrugCentral","snomedId":840539006,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"palivizumab","brandName":"palivizumab","genericName":"palivizumab","approvalYear":"1998","relationship":"same-class"},{"drugId":"ansuvimab","brandName":"ansuvimab","genericName":"ansuvimab","approvalYear":"2020","relationship":"same-class"},{"drugId":"imdevimab","brandName":"imdevimab","genericName":"imdevimab","approvalYear":"2020","relationship":"same-class"},{"drugId":"nirsevimab","brandName":"nirsevimab","genericName":"nirsevimab","approvalYear":"2023","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":["COVID-19"],"enrollment":3800,"completionDate":"2027-01"},{"nctId":"NCT05195060","phase":"","title":"TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-12-14","conditions":["COVID-19"],"enrollment":1178,"completionDate":"2025-09-01"},{"nctId":"NCT05081388","phase":"PHASE1,PHASE2","title":"COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-11-08","conditions":["SARS-CoV-2"],"enrollment":25,"completionDate":"2022-06-30"},{"nctId":"NCT05074433","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-10-25","conditions":["Immunocompromised"],"enrollment":66,"completionDate":"2022-05-18"},{"nctId":"NCT04992273","phase":"PHASE2","title":"COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-09-13","conditions":["COVID-19"],"enrollment":7,"completionDate":"2022-06-01"},{"nctId":"NCT04852978","phase":"PHASE2","title":"COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-04-29","conditions":["Healthy","Chronic Stable Illness"],"enrollment":295,"completionDate":"2022-11-21"},{"nctId":"NCT05092581","phase":"PHASE1","title":"COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-12-16","conditions":["COVID-19"],"enrollment":2,"completionDate":"2022-06-09"},{"nctId":"NCT05181683","phase":"PHASE1","title":"COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-01-07","conditions":["Healthy","Chronic Stable Illness"],"enrollment":45,"completionDate":"2022-06-03"},{"nctId":"NCT05013632","phase":"","title":"COVID-19 International Drug Pregnancy Registry","status":"RECRUITING","sponsor":"Pregistry","startDate":"2021-12-01","conditions":["Covid19"],"enrollment":2000,"completionDate":"2027-09-30"},{"nctId":"NCT04885452","phase":"","title":"Prevention of COVID-19 Complications in High-risk Subjects Infected by SARS-CoV-2 and Eligible for Treatment Under a Cohort ATU ('Autorisation Temporaire d'Utilisation') OR or Authorisation for Early Access (AAP). A Prospectvie Cohort.","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-09-21","conditions":["SARS-CoV Infection","Covid19"],"enrollment":756,"completionDate":"2023-12-18"},{"nctId":"NCT05268601","phase":"","title":"COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2","status":"COMPLETED","sponsor":"University of Milano Bicocca","startDate":"2021-10-14","conditions":["COVID-19"],"enrollment":251,"completionDate":"2023-12-22"},{"nctId":"NCT04790240","phase":"PHASE1,PHASE2","title":"Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)","status":"RECRUITING","sponsor":"All Natural Medicine Clinic, LLC","startDate":"2025-01-01","conditions":["Covid19 Virus Infection"],"enrollment":100,"completionDate":"2027-05-30"},{"nctId":"NCT05013723","phase":"","title":"Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome","status":"COMPLETED","sponsor":"Intermountain Health Care, Inc.","startDate":"2021-08-30","conditions":["Post-acute COVID-19 (PACS), or \"long COVID\" Syndrome"],"enrollment":260,"completionDate":"2022-12-16"},{"nctId":"NCT05271929","phase":"PHASE3","title":"Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19","status":"TERMINATED","sponsor":"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","startDate":"2022-04-01","conditions":["COVID-19"],"enrollment":120,"completionDate":"2024-06-17"},{"nctId":"NCT04518410","phase":"PHASE2,PHASE3","title":"ACTIV-2: A Study for Outpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-19","conditions":["Coronavirus","Covid19"],"enrollment":4044,"completionDate":"2023-06-20"},{"nctId":"NCT06233357","phase":"","title":"Critically Ill ICU Patients Under Casirivimab- and/or Tocilizumab Application","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2021-08-01","conditions":["COVID-19","Outcome, Fatal","Tocilizumab","Interleukin 6","Critically Ill"],"enrollment":95,"completionDate":"2023-12-31"},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":["Severe Acute Respiratory Syndrome"],"enrollment":70000,"completionDate":"2036-06-30"},{"nctId":"NCT04425629","phase":"PHASE3","title":"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-06-16","conditions":["COVID-19"],"enrollment":10078,"completionDate":"2022-06-09"},{"nctId":"NCT04617535","phase":"","title":"Compassionate Use of REGN-COV2 for the Treatment of COVID-19","status":"NO_LONGER_AVAILABLE","sponsor":"Regeneron Pharmaceuticals","startDate":"","conditions":["COVID-19"],"enrollment":0,"completionDate":""},{"nctId":"NCT05502081","phase":"PHASE4","title":"Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients","status":"COMPLETED","sponsor":"Mansoura University Hospital","startDate":"2022-09-02","conditions":["COVID-19"],"enrollment":265,"completionDate":"2022-12-28"},{"nctId":"NCT04790786","phase":"PHASE4","title":"UPMC OPTIMISE-C19 Trial, a COVID-19 Study","status":"TERMINATED","sponsor":"Erin McCreary","startDate":"2021-03-10","conditions":["Covid19"],"enrollment":4571,"completionDate":"2022-06-16"},{"nctId":"NCT04452318","phase":"PHASE3","title":"COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-07-13","conditions":["Healthy Participants"],"enrollment":3303,"completionDate":"2021-10-04"},{"nctId":"NCT04748588","phase":"PHASE4","title":"Treatment of Nosocomial COVID-19","status":"TERMINATED","sponsor":"University of Calgary","startDate":"2021-02-12","conditions":["Covid19","Nosocomial Infection","SARS-CoV2 Infection"],"enrollment":46,"completionDate":"2022-01-31"},{"nctId":"NCT04426695","phase":"PHASE1,PHASE2","title":"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-06-10","conditions":["COVID-19"],"enrollment":2252,"completionDate":"2021-10-22"},{"nctId":"NCT05205759","phase":"PHASE3","title":"Non-inferiority Trial on Monoclonal Antibodies in COVID-19","status":"TERMINATED","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2021-12-09","conditions":["COVID-19"],"enrollment":319,"completionDate":"2022-04-05"},{"nctId":"NCT05439044","phase":"","title":"A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-03-01","conditions":["Immunocompromised Patients"],"enrollment":4000,"completionDate":"2022-12-31"},{"nctId":"NCT05157997","phase":"PHASE1","title":"Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail","status":"WITHDRAWN","sponsor":"Northwell Health","startDate":"2022-01","conditions":["COVID-19","Organ Transplant"],"enrollment":0,"completionDate":"2025-01"},{"nctId":"NCT04666441","phase":"PHASE2","title":"COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-12-15","conditions":["COVID-19"],"enrollment":1149,"completionDate":"2021-09-21"},{"nctId":"NCT04840459","phase":"PHASE2","title":"Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting","status":"UNKNOWN","sponsor":"Sohail Rao","startDate":"2020-11-20","conditions":["Covid19"],"enrollment":1000,"completionDate":"2023-01-31"},{"nctId":"NCT04519437","phase":"PHASE1","title":"Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-07-26","conditions":["Healthy","Chronic Stable Illness"],"enrollment":974,"completionDate":"2021-11-22"}],"_emaApprovals":[{"date":"2021-11-12","status":"Authorised","company":"ROCHE REGISTRATION GMBH"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"Casirivimab"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"REGEN-COV"}]},"crossReferences":{"MMSL":"341252","NDDF":"018563","UNII":"J0FI6WE1QN","VANDF":"4039878","INN_ID":"11861","RXNORM":"2465242","UMLSCUI":"C5422688","chemblId":"CHEMBL4650248","ChEMBL_ID":"CHEMBL4650248","KEGG_DRUG":"D11938","DRUGBANK_ID":"DB15941","SNOMEDCT_US":"1137366009","IUPHAR_LIGAND_ID":"11327","SECONDARY_CAS_RN":"2415933-42-3","MESH_SUPPLEMENTAL_RECORD_UI":"C000711751"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","company":"Regeneron Pharmaceuticals, Inc.","brandName":"REGEN-COV","isOriginal":true,"marketingStatus":"UNAPPROVED DRUG OTHER"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2020-","companyName":"Regeneron Pharmaceuticals, Inc.","relationship":"Original Developer"},{"period":"2021","companyName":"CHUGAI PHARMACEUTICAL Co., Ltd","relationship":"PMDA Licensee"},{"period":"2021","companyName":"Roche Registration Gmbh","relationship":"EMA Licensee"}],"publicationCount":395,"therapeuticAreas":["Infectious Disease"],"_revenueScrapedAt":"2026-03-31 10:40:47.972067+00","atcClassification":{"source":"DrugCentral","atcCode":"J06BD07","allCodes":["J06BD07"]},"biosimilarFilings":[],"originalDeveloper":"Regeneron Pharmaceuticals, Inc.","recentPublications":[{"date":"2026","pmid":"41884818","title":"The role of large immune complexes in anti-drug antibody development: a case study of anti-SARS-CoV-2 antibody therapeutics and co-administered mRNA vaccine.","journal":"Frontiers in immunology"},{"date":"2026 Feb 28","pmid":"41771484","title":"Effect of background asthma and allergic conditions on prophylaxis and treatment of COVID-19 infection.","journal":"Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology"},{"date":"2026 Jan 29","pmid":"41612083","title":"Value of Emerging and Existing Pre-prophylaxis and Therapeutic Options for COVID-19 in Transplant Recipients: A Systematic Review of Economic Evaluations.","journal":"PharmacoEconomics - open"},{"date":"2026 Jan 4","pmid":"41598229","title":"REGEN-COV as the First Line of Defense-A Single-Centre Experience.","journal":"Life (Basel, Switzerland)"},{"date":"2025 Oct 20","pmid":"41278696","title":"A cocktail of SARS-CoV-2 spike stem helix domain and receptor binding domain human monoclonal antibodies prevent the emerge of viral escape mutants.","journal":"bioRxiv : the preprint server for biology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Regeneron Pharmaceuticals, Inc.","companyId":"regeneron","modality":"Monoclonal antibody","firstApprovalDate":"2020","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:27:29.463539+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}